New drug adds to arsenal against AIDS

July 15, 2011

A new drug, rilpivirine, can add powerfully to the combination of medications used to control HIV for first-time patients, researchers conclude in Friday's issue of The Lancet.

Rilpivirine, marketed by pharmaceutical firm Tibotec under the brand name of Edurant, is both safe and effective and its side effects are fewer and less severe compared with the widely-used efavirenz, or Sustiva, they say.

Combination therapy for new commonly entails giving either efavirenz or nevirapine in conjunction with drugs of a separate class in order to attack the (HIV) from different angles.

Efavirenz and nevirapine are equally effective at suppressing HIV but can cause severe side effects, which is why there has been a search for a substitute drug in their class.

The two studies report on data from two trials carried out among nearly 1,400 patients in 21 countries.

Rilpivirine, a so-called second generation antiretroviral, was approved for combination therapy in May by the (FDA).

The study appears in the runup to a four-day medical conference, starting in Rome on Sunday, on the state of the HIV/AIDS pandemic.

Acquired immune deficiency syndrome (AIDS) has claimed some 30 million lives since the first recorded cases emerged in June 1981. At least 33 million people are living with HIV, according to UN estimates for 2009.

Related Stories

Recommended for you

HIV exports viral protein in cellular packages

February 15, 2018
HIV may be able to affect cells it can't directly infect by packaging a key protein within the host's cellular mail and sending it out into the body, according to a new study out of a University of North Carolina Lineberger ...

Can gene therapy be harnessed to fight the AIDS virus?

February 13, 2018
For more than a decade, the strongest AIDS drugs could not fully control Matt Chappell's HIV infection. Now his body controls it by itself, and researchers are trying to perfect the gene editing that made this possible.

Big data methods applied to the fitness landscape of the HIV envelope protein

February 7, 2018
Despite significant advances in medicine, there is still no effective vaccine for the human immunodeficiency virus (HIV), although recent hope has emerged through the discovery of antibodies capable of neutralizing diverse ...

Scientists report big improvements in HIV vaccine production

February 5, 2018
Research on HIV over the past decade has led to many promising ideas for vaccines to prevent infection by the AIDS virus, but very few candidate vaccines have been tested in clinical trials. One reason for this is the technical ...

Microbiome research refines HIV risk for women

January 25, 2018
Drawing from data collected for years by AIDS researchers in six African nations, scientists have pinpointed seven bacterial species whose presence in high concentrations may significantly increase the risk of HIV infection ...

Researchers find latent HIV reservoirs inherently resistant to elimination by CD8+ T-cells

January 22, 2018
The latest "kick-and-kill" research to eliminate the HIV virus uncovered a potential obstacle in finding a cure. A recent study by researchers at the George Washington University (GW) found that latent HIV reservoirs show ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.